Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AEZS Annotated Chart - getting into the "keep a good eye on the chart" area. JMHO Things can definitely over cook, many do, most will act more like an elastic band shoot up, then let go and retract and then perhaps move up again.
This stock seems, jmho, like it is nearing an area where I would definitely keep an eye on it. If nothing else profit taking may cause a retrace. Watch the Resistance lines and the bolli bands along with the $$$ flow on the chart, without +++ $$$ flow the SP will dip back. JMHO Nice if you have it just watch carefully next few sessions for either an opportunity to sell or an opportunity to buy more if you choose.
THLD Ph3 6/30/14 perhaps early, but no debt and a fair amount of cash and a small short % of float.
http://wallstcheatsheet.com/stocks/its-time-to-pay-attention-to-threshold-pharmaceuticals.html/?ref=YF
CJ looks like you made some vg choices, a few have gone up sharply since 12/1. kudos Buddy
T2M
Sheff excellent advise however how do we in particular know when and what they are buying? Is it listed somewhere?
TIA
T2m
Merry Xmas - Happy and Safe Holidays
T2M
Merry Xmas to ALL! Big Kudos to Sheff for taking the time to moderate an excellent board and to do it for so many years. I'm sure it is greatly appreciated that he shares his trades and talent with a huge number of us on a daily basis.
Wishing you all Happy and Safe Holidays!
T2M
IGXT Kei- yes just hanging on tight and waiting for a move up to PDUFA, guess we shall see before too long what happens.
NWBO <down 6%> on my last little misadventure, but since getting stopped out 12/11 at 4.23 the stock fell a lot and since has come back quite a bit and imo likely is very near basing, (hope I am correct on that one). It should have some good upside as a cancer stock with an indefinite timing for its PH3, though it is listed as Jan 31, 2014.
When the required events finish this has a huge upside potential and looking at a weekly chart not a huge downside one. jmho
Maybe sitting with it for a week or several months, much more likely the later. jmho
MNKD Bought some as early bird special on 4/15 PDUFA, although it would have been far cheaper to get it a bit ago when Sheff did his post. I will get another chunk on a dip to average out.
IGXT Holding a bunch at .52 awaiting a run up for 2/3/14 PDUFA.
ARIA auto profit exit 25.8% on 1/2 of position.
Merry Christmas Goodfellas! May we all have Happy and Safe Holidays and a prosperous 2014
Best 2 U ALL,
T2M
CANF RTN it is having a great premarket, though the liquidity is near non-existant hence the CEP's comment. Looks like a good flipping candidate long as you don't buy tooooo much and get trapped. Imho any new novice investors should watch any stop loss type orders they put in on it, since this has very very few shares OS and is thinly traded, it is very volatile, hence a stop order going to market could be a huge intraday whipsaw for you. With that in mind though it is a good find and even better last week. lol
RTN thanks for the interesting stock, looks like you have done very well thus far on it, have you had it long?
BOL
T2M
Cabos - just have my fingers crossed, but it sure logically seems like it should move up now with the same cancer drug which caused the huge SP drop a while back from 17-20 to 2.62 and then even a bit lower being now in Jan started up again.
jmhg but I am going to hold on for a while.
ARIA I agree wholeheartedly and will use dips to buy here and there.
BOL
OMax
[img]
Click here: Guess My Gift: A Gift from OfficeMax
[/img]
PVCT High CN I flipped out a while back on 12/13 @ 1.38 likely an auto trigger. Haven't relooked until your post, seems like it continue a bit more yet. Hopefully you have done well on it, it was VG to me.
ARIA has been my latest flipper and core holder. News today imo will take it up for the next few weeks. 18% short of float and this HUGE gap it has to fill was created by them pulling this drug off the market months ago. It was a $17-20 stock.
I'm thinking I will scalp a bunch on it in the coming days/weeks. Guess I shall see.
10:10AM Ariad Pharm announces U.S. resumption of marketing and commercial distribution of Iclusig (ponatinib) in refractory Philadelphia-positive leukemias (ARIA) 6.31 +0.79 : Co announced that the FDA has approved revised U.S. Prescribing Information (USPI) and a Risk Evaluation and Mitigation Strategy (REMS) for Iclusig (ponatinib) that allows immediate resumption of its marketing and commercial distribution. The USPI includes a revised indication statement and boxed warning, updated safety information and recommendations regarding dosing considerations for prescribers. Iclusig is now indicated for the treatment of adult patients with:
T315I-positive chronic myeloid leukemia (chronic phase, accelerated phase, or blast phase) or T315I-positive Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia, and
Chronic phase, accelerated phase, or blast phase chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia for whom no other tyrosine-kinase inhibitor therapy is indicated.
The FDA granted approval of the revised USPI based on its review of the Iclusig clinical-trial data, including 24-month follow up of the pivotal PACE trial. The boxed warning has been revised to alert patients and healthcare professionals to the risk of vascular occlusive events and includes a new warning for heart failure. The starting dose of Iclusig remains 45 mg daily.
At the end of October 2013, there were approximately 640 patients receiving Iclusig obtained through commercial channels in the U.S. Since then, Iclusig has been made available through emergency and single-patient investigational new drug (IND) applications, which were reviewed and approved by the FDA on a case-by-case basis. Through today, FDA has approved 350 INDs. This figure includes approximately 260 patients who have already received Iclusig and approximately 90 additional patients who have been approved to receive Iclusig through these mechanisms.
ARIAD management will host a conference call and webcast to discuss the approval of a new U.S. product label for Iclusig today, December 20 at 11:30 a.m. ET.
ARIA The news that made this pop imo is likely to have legs, since the gap was caused by the same drug being pulled.
10:10AM Ariad Pharm announces U.S. resumption of marketing and commercial distribution of Iclusig (ponatinib) in refractory Philadelphia-positive leukemias (ARIA) 6.31 +0.79 : Co announced that the FDA has approved revised U.S. Prescribing Information (USPI) and a Risk Evaluation and Mitigation Strategy (REMS) for Iclusig (ponatinib) that allows immediate resumption of its marketing and commercial distribution. The USPI includes a revised indication statement and boxed warning, updated safety information and recommendations regarding dosing considerations for prescribers. Iclusig is now indicated for the treatment of adult patients with:
T315I-positive chronic myeloid leukemia (chronic phase, accelerated phase, or blast phase) or T315I-positive Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia, and
Chronic phase, accelerated phase, or blast phase chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia for whom no other tyrosine-kinase inhibitor therapy is indicated.
The FDA granted approval of the revised USPI based on its review of the Iclusig clinical-trial data, including 24-month follow up of the pivotal PACE trial. The boxed warning has been revised to alert patients and healthcare professionals to the risk of vascular occlusive events and includes a new warning for heart failure. The starting dose of Iclusig remains 45 mg daily.
At the end of October 2013, there were approximately 640 patients receiving Iclusig obtained through commercial channels in the U.S. Since then, Iclusig has been made available through emergency and single-patient investigational new drug (IND) applications, which were reviewed and approved by the FDA on a case-by-case basis. Through today, FDA has approved 350 INDs. This figure includes approximately 260 patients who have already received Iclusig and approximately 90 additional patients who have been approved to receive Iclusig through these mechanisms.
ARIAD management will host a conference call and webcast to discuss the approval of a new U.S. product label for Iclusig today, December 20 at 11:30 a.m. ET.
Kipper I like to chart things I own, imo it tends to make the guessing more objective and places some constraint since I use support and resistance a lot.
ARIA Should be interesting to see what the 18% of the float that was short does and when. Company has plenty of cash, so another stock issue is not likely imho
Smart$ if we look at where the stock was priced prior to the withdrawl of that drug it may well give a clue of the potential of the SP over a 4-6 weeks, jmvhg per the chart I put up.
SF ARIA yes the restart of the cancer drug in Mid Jan should move this up a fair bit over the 1st qtr imo. THen the SP will likely be fully priced. JMHG
I was flipping it as late as this morning and luckily had core shares during today's news halt. This has been super to me, 14+% yesterday then again entered in another account only to have trading shares sell off this morning at another 18% up and the core shares continue to climb,
VN one imho.
T2M
Panda, very well put, and in Sheff's case very much deserved. I think most all of us strongly second the sentiment.
"Message in reply to Sheff:
$heff, As we come to Christmas and New Years of another year of investing I just wanted to be the first to come forward this year and thank you for what you have done. I have had a good year and I know many others on this board have. Your constant study and willingness to share has been a positive influence on all of us again.
Merry Christmas, Happy New Year
The Panda "
BOL
T2M
ARIA man if you did option you must be very happy, I only fip the stock a fair bit and it has been very nice. Just waiting and seeing on the latest bunch I have. Thinking the resumption of sales of this cancer drug may have some legs, judging from the way it is trading I think so anyway.
Fingers are crossed.
ARIA Wow that was super lucky 200MA at 12.89 and huge gap if it fills this time, glad I kept the 1/2, bloomberg came out with its announcement within 3 minutes after I traded that bunch before, then a trading halt then resumption and way up.
They are bringing cancer drug Inclusig back for sale by mid Jan.
ARIA sold some flipping shares I bought back in another account yesterday.
18% gain on 1/2 today, have 1/2 of them left for later so my fingers are crossed,
This one thus far has been very kind, hope it keeps it up.
Whas vg approach imo since you are very correct last I looked.
ALIM auto profit exit at 107% wow!! Just returned from consulting to find that it sold automatically. Made my day! In at 2.24+ and out at 4.64+ Wow nice xmas present. Still chipping away at that GTXI paper loss made months earlier.
Merry Xmas 2 me and u
T2M
ALIM auto profit exit at 107% wow!! Just returned from consulting to find that it sold automatically. Made my day! In at 2.24+ and out at 4.64+ Wow nice xmas present. Still chipping away at that GTXI paper loss made months earlier.
KS great endorsement, the wife and I both have a pair. In NH they are very useful; I sure see why she got them 5 years back.
Walked 3.7M yesterday and 3.4 today on snowy icy dirt roads but not a slip, up and down some steep hills. Great product, they now are my winter favorite, along with my superfeet insoles.
The superfeet from EMS I wear year round to prevent plantar fasciitis, had that 5-7 years back, painful. The podiatrist suggested them by name (since podiatrists patented them and they work), rather than very expensive custom made products to cure and prevent. Had them ever since. He said there are a ton of insoles but the vast vast majority don't work or work for a month. These seem to last about a year, then need to be replaced.
Think I have 6 pair of them now, some for hiking, some for casual and some for walking.
Great getting older, but it sure beats the alternative.
back-- well just in case I dropped back on the push ups to 30 a day, should be fine and that way not an issue but it tones++/
Wife gave me yacks (sp) 5 years ago. You slip them on over shoes/boots. They are very light weight and act as mini chains on your feet in the ice and snow. I used them on the snowy/icy dirt roads yesterday and today went about 3.7miles each day in them and wow they work fantastically, did not slip at all, so at 66 I am very happy about that. Funny I had them for so long, and had never used them. They were like new out of the package, my wife said to use them due to my hip and the ice, great invention for this ole guy lol
LH my anniversary lol
back2basics
good to know, interesting, never heard that before.
I have annual checkups and will be sure to ask my doc about it. You would think if that result happened to one muscle group, ie arms in your case, it should in theory also happen to another, ie legs from walking.
Very strange. I will also ask my daughter. She majored in exercise therapy in college, and now, designs and runs a major fitness programs for a large corp.
Thanks for the heads up, better safe than sorry.
PVCT auto-profit exit triggered today at 35.5% so I am now out and will review any retrace.
This one did not take very long at all.
BOL